Overview
Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product.
ICON panelists will bring their perspectives on critical issues around support for a product’s fair market price.
Key discussion topics
- Outline how CMS might select the 10 products that will be required to negotiate their prices this fall
- Describe how CMS will determine fair market prices for Medicare Part D drugs
- Suggest actions that manufacturers could take in response to the Medicare Part D price negotiation requirements
Moderator:
Mark McCoy
Director Client Engagement, ICON Pricing, Market Access & Reimbursement
ICON panelists:
.png?crop=yes&w=240&h=240&itok=P-WWASI1){kind=icon}
Earlene Biggs
Divisional Principal, Market Access
Bruce Capobianco
Senior Director, Real World Evidence
Tanja Obradovic
VP, Scientific Affairs, Oncology Medical Strategy
Ki Park
VP Patient Insight, Market Access & Commercial
Nancy Risebrough
Senior Principal, Global HEOR
Audience
This webinar will benefit pharmaceutical and biotech professionals in the following areas:
- Channel Marketing
- Clinical
- Competitive Intelligence
- Government Affairs
- Health Economics and Outcomes Research
- Market Access
- Marketing
- Managed Markets
- Market Research
- Real World Evidence
- Regulatory Affairs